He served as member on the European Organisation for Research and Treatment of Cancer (EORTC) Protocol Review Committee (PRC) and Scientific Audit Committee (SAC), as chair of the EORTC Preclinical Therapeutic Models Group (PTMG) and on the EORTC New Drug Advisory Committee (NDAC). He functioned as member on the EORTC Board of Directors as well as its Executive Committee and as chair of the EORTC Translational Research Division (TRD).

He was chairman of the Fellowship and Award Committee of the European Society for Medical Oncology (ESMO) and ESMO representative in the Board and Council of the FECS, nowadays ECCO, as well as ESMO national representative of Austria. He was coordinator of the ESMO Faculty for Principles of Clinical Trials and Systemic Therapy as well as faculty member/co-director of the Clinical Trials Workshops in Flims/Zeist, representing ESMO. Actually, he functions as core member of the ESMO EU Policy Committee and as past chair of the ESMO/ASCO Global Curriculum Working Group.

He was running a CME-initiative in trials methodology in German language under the patronage of DESO for two decades. He was acting as principal or co-investigator in numerous clinical trials from phase I to phase III. He has research interests in clinical trials’ methodology, new drug development and translational research, focused on solid tumors.